Visiopharm and Hamamatsu Announce Worldwide OEM Agreement
News Jul 09, 2012
Visiopharm and Hamamatsu have announced a non-exclusive worldwide original equipment manufacturer (OEM) agreement and reseller partnership for Visiopharm’s Quantitative Digital Pathology (QDP) solutions.
Under the partnership, Visiopharm will be an OEM for Hamamatsu’s new NDP.analyze software, a research tool for tissue image analysis, which is fully compatible with Visiopharm’s entire suite of QDP solutions.
Hamamatsu will market and sell the entire suite of QDP solutions, including CloudAnalysis, DeployedAnalysis, Stereology, and Application Protocol Packages (APPs) from Visiopharm’s new APPCenter.
NDP.analyze will be exhibited at Analytica 2012, 17th to 20th April 2012, in Munich, Germany.
Hamamatsu, who is known throughout the world for their NanoZoomer Digital Pathology (NDP) whole slide scanners, will expand their offering in digital pathology to include quantitative digital pathology.
The full range of analysis solutions are integrated with the NDP.serve data management software. The software will be available directly from Hamamatsu worldwide.
Masafumi Oshiro, Product Manager of Hamamatsu Photonics, stated “Hamamatsu is committed to provide complete solutions of high quality to its customers. Image analysis is becoming an increasingly important part of Digital Pathology. With the NDP.analyze and the software from Visiopharm fully integrated in the NDP environment, we are now able to provide a powerful image analysis solution. This powerful solution scales across the needs from individual academic researchers to large pharmaceutical companies with a regular and high-volume need for analysis. We are pleased to be able to offer image analysis APPs that provide a risk-free approach to image analysis for our customers and at the same time, provide immediate productivity with a very low learning curve.
NDP.analyze integrated with Visiopharm’s innovative solutions for QDP, will provide Hamamatsu customers with leading technology and flexible options, including analysis of NanoZoomer whole slide images in the Cloud and unlimited access to Visiopharm’s patent-pending APPCenter.
The APPCenter will provide both new and existing NanoZoomer and Visiopharm customers with innovative, affordable options for their deployed solutions, but also allow them to expand their efforts to collaborate and share data in the Cloud.
CloudAnalysis is an easy to budget solution for Hamamatsu customers who need access to sophisticated image analysis capabilities for a specific project which is limited in time.
Whether it is for a week, a month or longer, customers will only pay for analysis when they need it. Hamamatsu customers can now have instant access, and will be able to analyze whole slide images from work, home, or from anywhere.
Michael Grunkin PhD, CEO of Visiopharm, stated “We are very impressed with Hamamatsu and their innovative vision for digital pathology. The NanoZoomer is a very robust product capable of providing scanned images of a consistent high quality and with a very competitive scan speed. It is clear to us that Hamamatsu will play an important role in providing integrated and complete quality solutions to the research market. An OEM agreement and reseller partnership with Hamamatsu will expand the availability of Visiopharm’s QDP solutions worldwide, and enable the rapidly growing digital pathology market to work in an efficient, integrated digital workflow with Hamamatsu’s NanoZoomer Digital Pathology solutions.
A new platform ensures that web services adhere to users’ preferences on how their data are stored and shared in the cloud. In a paper being presented at this week’s USENIX Networked Systems Design and Implementation conference, the researchers behind the platform, called Riverbed, show how it forces data center servers to only use data in ways that users explicitly approve.READ MORE
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE